IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY
The present invention relates generally to the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with express...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre ; ger |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | XIAO, Qitao MAVRAKIAS, Konstantinos John LIU, Lei ZHENG, Qiangang MOTZ, Gregory LIU, Jinbiao XUN, Guoliang |
| description | The present invention relates generally to the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP3397756A4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP3397756A4</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP3397756A43</originalsourceid><addsrcrecordid>eNrjZDD19PUN9XNVcHVzc3UO8Q9ScHb18VEI8XANcgzwdA1WCPcM8VBw9fNw9HN2dQGp8nR2dI7kYWBNS8wpTuWF0twMCm6uIc4euqkF-fGpxQWJyal5qSXxrgHGxpbm5qZmjibGRCgBAIxUJyQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY</title><source>esp@cenet</source><creator>XIAO, Qitao ; MAVRAKIAS, Konstantinos John ; LIU, Lei ; ZHENG, Qiangang ; MOTZ, Gregory ; LIU, Jinbiao ; XUN, Guoliang</creator><creatorcontrib>XIAO, Qitao ; MAVRAKIAS, Konstantinos John ; LIU, Lei ; ZHENG, Qiangang ; MOTZ, Gregory ; LIU, Jinbiao ; XUN, Guoliang</creatorcontrib><description>The present invention relates generally to the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.</description><language>eng ; fre ; ger</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2019</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20191204&DB=EPODOC&CC=EP&NR=3397756A4$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20191204&DB=EPODOC&CC=EP&NR=3397756A4$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>XIAO, Qitao</creatorcontrib><creatorcontrib>MAVRAKIAS, Konstantinos John</creatorcontrib><creatorcontrib>LIU, Lei</creatorcontrib><creatorcontrib>ZHENG, Qiangang</creatorcontrib><creatorcontrib>MOTZ, Gregory</creatorcontrib><creatorcontrib>LIU, Jinbiao</creatorcontrib><creatorcontrib>XUN, Guoliang</creatorcontrib><title>IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY</title><description>The present invention relates generally to the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2019</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDD19PUN9XNVcHVzc3UO8Q9ScHb18VEI8XANcgzwdA1WCPcM8VBw9fNw9HN2dQGp8nR2dI7kYWBNS8wpTuWF0twMCm6uIc4euqkF-fGpxQWJyal5qSXxrgHGxpbm5qZmjibGRCgBAIxUJyQ</recordid><startdate>20191204</startdate><enddate>20191204</enddate><creator>XIAO, Qitao</creator><creator>MAVRAKIAS, Konstantinos John</creator><creator>LIU, Lei</creator><creator>ZHENG, Qiangang</creator><creator>MOTZ, Gregory</creator><creator>LIU, Jinbiao</creator><creator>XUN, Guoliang</creator><scope>EVB</scope></search><sort><creationdate>20191204</creationdate><title>IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY</title><author>XIAO, Qitao ; MAVRAKIAS, Konstantinos John ; LIU, Lei ; ZHENG, Qiangang ; MOTZ, Gregory ; LIU, Jinbiao ; XUN, Guoliang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP3397756A43</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2019</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>XIAO, Qitao</creatorcontrib><creatorcontrib>MAVRAKIAS, Konstantinos John</creatorcontrib><creatorcontrib>LIU, Lei</creatorcontrib><creatorcontrib>ZHENG, Qiangang</creatorcontrib><creatorcontrib>MOTZ, Gregory</creatorcontrib><creatorcontrib>LIU, Jinbiao</creatorcontrib><creatorcontrib>XUN, Guoliang</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>XIAO, Qitao</au><au>MAVRAKIAS, Konstantinos John</au><au>LIU, Lei</au><au>ZHENG, Qiangang</au><au>MOTZ, Gregory</au><au>LIU, Jinbiao</au><au>XUN, Guoliang</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY</title><date>2019-12-04</date><risdate>2019</risdate><abstract>The present invention relates generally to the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre ; ger |
| recordid | cdi_epo_espacenet_EP3397756A4 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T13%3A37%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=XIAO,%20Qitao&rft.date=2019-12-04&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP3397756A4%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |